Key result
Opioid blockade with naltrexone increased salivary cortisol levels and pain ratings compared to placebo, with effects on pain being more pronounced in women.
Why the study?
Does opioid blockade with naltrexone alter adrenocortical and nociceptive responses in hypertension-prone men and women compared to placebo?
RCT (n=99)
Double-blind
counterbalanced
Does opioid blockade with naltrexone alter adrenocortical and nociceptive responses in hypertension-prone men and women compared to placebo?
Opioid blockade with naltrexone increases cortisol and pain responses, revealing that hypoalgesia may serve as a marker of hypertension risk in men.
Answers are grounded in this paper and cite their sources.
Opioid blockade heightens cortisol and pain reactivity in hypertension-prone adults; extends evidence linking hypoalgesia to hypertension risk with sex-specific patterns.
OBJECTIVE: Attenuated pain sensitivity and exaggerated adrenocortical stress reactivity have been documented in individuals at high risk for hypertension. The endogenous opioid system may play a role in these response alterations. We compared adrenocortical and nociceptive responses to opioid blockade using naltrexone in hypertension-prone men and women. METHODS: Ninety-nine participants completed two sessions during which a placebo or 50 mg naltrexone was administered using a double-blind, counterbalanced design. Participants rated their pain and completed the McGill Pain Questionnaire (MPQ) after three assessments of the nociceptive flexion reflex and after assessment of nociceptive pain threshold and tolerance. Saliva samples were obtained throughout the sessions. RESULTS: Salivary cortisol levels increased after pain assessment after the ingestion of naltrexone, but not after placebo, with the low-risk group exhibiting an earlier peak of cortisol response. Participants reported greater pain ratings and higher MPQ scores in the naltrexone versus placebo condition, and these effects were more pronounced in women. Pain threshold and tolerance were higher among high-risk men relative to low-risk men. CONCLUSIONS: The results are consistent with the inhibitory effects of the endogenous opioids on cortisol response and suggest an altered response timeline among hypertension-prone individuals. The results demonstrate that hypoalgesia may be a marker of hypertension risk in men but not in women.
No takes yet. Share an insight, caveat, or question.
Al’Absi et al. (2006) conducted an RCT in Hypertension risk (n=99). Naltrexone vs. Placebo was evaluated on Adrenocortical and nociceptive responses (salivary cortisol levels, pain ratings, MPQ scores, pain threshold and tolerance). Opioid blockade with naltrexone increased salivary cortisol levels and pain ratings compared to placebo, with effects on pain being more pronounced in women.
Synapse has enriched 10 related papers. Consider them for comparative context: